CCG-203971

Description: CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 µM), with 87% inhibition of SRE activation achieved at 100 µM. This compound also inhibits PC-3 cell migration (IC50: 4.2 µM), as determined by a scratch wound assay. CCG-203971(CCG203971) causes no cytotoxicity when evaluated by the WST-1 assay. It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days. Target: Ras, Rho. Smiles: Clc1ccc(NC(=O)C2CCCN(C2)C(=O)c2cccc(c2)-c2ccco2)cc1. References: Haak AJ, et al. Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J Pharmacol Exp Ther. 2014 Jun,349(3):480-6.